Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases

Rhea-AI Summary

Medicxi (NYSE: LLY) announces the acquisition of its portfolio company, Versanis Bio, by Eli Lilly and Company for up to $1.925 billion USD in cash. Versanis is focused on developing new medicines for cardiometabolic diseases, with its lead asset, bimagrumab, currently being assessed in a Phase 2b study for the treatment of overweight or obesity. This acquisition reinforces Medicxi's commitment to investing in asset-driven companies and its belief in the therapeutic potential of bimagrumab in improving patient outcomes.

Positive

• Medicxi's successful exit of Versanis Bio through acquisition by Eli Lilly and Company demonstrates the firm's ability to generate substantial returns on its investments. The acquisition amount of up to $1.925 billion USD signifies the value of Versanis' lead asset, bimagrumab, and its potential to address unmet needs in the treatment of cardiometabolic diseases.

Negative

• None.

• Medicxi co-led Company's US$70 million Series A less than 2 years ago
• Third Medicxi portfolio exit to US biopharma in last 12 months

LONDON, GENEVA and JERSEY, British Isles, July 14, 2023 /PRNewswire/ -- Medicxi, a leading European life sciences investment firm, announces that its portfolio company, Versanis Bio, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases, has entered into a definitive agreement to be acquired by Eli Lilly and Company (NYSE: LLY). Under the terms of the agreement, which is subject to customary conditions, Versanis shareholders would receive up to $1.925 billion USD in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain development and sales milestones.

Versanis was founded in 2021 by biotech investment firm Aditum Bio to develop bimagrumab for the treatment of metabolic diseases and obesity following its in-licensing from Novartis. Medicxi invested in the company in August 2021 when it co-led a $70 million Series A financing with Atlas Venture. Nick Williams, Partner at Medicxi, led the investment and is a member of the Versanis Board of Directors.

Versanis' lead asset is bimagrumab, a first-in-class, fully human monoclonal antibody to activin type II receptors that blocks binding of ligands including myostatin, activins, and GDF11. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study alone or in combination with semaglutide in adults living with overweight or obesity. Combining incretins with bimagrumab has the potential to improve the quality and durability of weight loss, with the goal of achieving better outcomes for people living with obesity and obesity-related complications. 

Nick Williams, Partner at Medicxi, said: "The acquisition of Versanis reinforces our belief in the importance of body composition when considering the therapeutic management of obesity. Bimagrumab exhibits a differentiated clinical profile, with the potential to achieve meaningful body fat loss whilst at the same time increasing muscle mass. This single-asset exit further strengthens our belief in delivering value via investing in focused, asset-driven companies. We are extremely excited to be partnering with an experienced organisation like Lilly that will continue to develop bimagrumab in combination with its portfolio of incretins to improve patient outcomes in cardiometabolic diseases."

Notes to Editors

About Medicxi

Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need. For more information, please visit: https://www.medicxi.com

About Versanis

Versanis is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease. The company's lead asset, bimagrumab, is being advanced in the BELIEVE Phase 2b study as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow. Versanis was founded in 2021 by Aditum Bio. For more information, please visit www.versanisbio.com.

 

View original content:https://www.prnewswire.com/news-releases/medicxi-asset-centric-portfolio-company-versanis-bio-to-be-acquired-by-lilly-to-improve-patient-outcomes-in-cardiometabolic-diseases-301877433.html

SOURCE Medicxi

FAQ

What is the acquisition announcement involving Medicxi and Versanis Bio?

Medicxi announces the acquisition of its portfolio company, Versanis Bio, by Eli Lilly and Company for up to $1.925 billion USD in cash.

What is Versanis Bio focused on?

Versanis Bio is focused on developing new medicines for the treatment of cardiometabolic diseases, with its lead asset, bimagrumab, currently being assessed in a Phase 2b study for the treatment of overweight or obesity.

What is the significance of the acquisition for Medicxi?

The acquisition reinforces Medicxi's commitment to investing in asset-driven companies and its belief in the therapeutic potential of bimagrumab in improving patient outcomes.